SCHEMBL4675686

SCHEMBL4675686

O=C(C=C(O)c1nn[nH]n1)c1cn(Cc2cccc(F)c2)cc1CCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.38
NCEH1 Q6PIU2 1/20 0.38
FFAR2 O15552 1/20 0.37
KDM4C Q9H3R0 1/20 0.36
PTGER4 P35408 1/20 0.35
PTGER2 P43116 1/20 0.35
BRS3 P32247 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
GPR52 Q9Y2T5 1/20 0.34
PIN1 Q13526 1/20 0.34
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
THRB P10828 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
PLA2G4A P47712 1/20 0.33
NR3C2 P08235 1/20 0.33
NTRK1 P04629 1/20 0.33
ALDH1A1 P00352 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675325 0.91 PTGDR2 (0.37) CES1NCEH1FFAR2KDM4CHCAR2
SCHEMBL4679350 0.91 CES1 (0.39) CES1NCEH1PTGER4PTGER2PLA2G4A
SCHEMBL4676460 0.91 CES1 (0.43) CES1NCEH1PLA2G4A
SCHEMBL4673837 0.87 CES1 (0.39) CES1NCEH1KDM4CBRS3GPR52
SCHEMBL4674218 0.86 CES1 (0.40) CES1NCEH1HCAR2GPR52PLA2G4A
SCHEMBL4676215 0.86 KDM4C (0.38) KDM4CPTGER4PTGER2BRS3HCAR2
SCHEMBL4674328 0.85 CES1 (0.39) CES1NCEH1GPR52PLA2G4AALDH1A1
SCHEMBL4674667 0.85 CES1 (0.39) CES1NCEH1PLA2G4A
SCHEMBL4675233 0.84 CES1 (0.38) CES1NCEH1LMNAPLA2G4A
SCHEMBL4676235 0.83 CDK5 (0.38) CES1NCEH1GPR52PLA2G4AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885FFAR2 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.